98 completed, 19 unknown, 7 recruiting, 4 terminated. 43 Phase 2, 28 Phase 4, 24 Phase 1, 21 Phase 3, 15 Not applicable.
Follow Levodopa: new trials by email Literature Review of Levodopa trials Research Report on Levodopa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gastrointestinal Dopamine Decarboxylase and Levodopa Pharmacokinetics Levodopa (L-dopa) - Parkinson's Disease | Phase 4 | Not yet recruiting | Beth Israel Deaconess Medical Center | 40 | 2027-07-01 | 2026-08-28 |
| Brain Dopamine Biomarker Levadopa/Carbidopa eyedrops, Sham, Levodopa/Carbidopa (Sinemet) - Parkinson Disease, Healthy Adult Participants | Not yet recruiting | University of South Florida | 50 | 2026-10-01 | 2026-08-12 | |
| Study of L-dopa Treatment in Patients With a Neurodevelopmental Disorder (CTNNB1 Gene) L-Dopa - CTNNB1, L-DOPA | Not applicable | Recruiting | University Hospital, Montpellier | 7 | 2026-04-08 | 2026-05-29 |
| Etoricoxib in Patients With Parkinsonian Disease L-dopa, Etoricoxib - Parkinson Disease | Phase 2 | Recruiting | Ihab Elsayed Hassan | 60 | 2026-01-30 | 2026-04-08 |
| Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease LECIG (levodopa, carbidopa, entacapone intestinal gel), Best oral medication - PARKINSON DISEASE (Disorder) | Phase 3 | Recruiting | University Hospital Tuebingen | 150 | 2025-10-27 | 2026-07-13 |
| Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease. Administration of Carbidopa/levodopa - Multi-system Atrophy - Parkinsonian Type, Orthostatic Hypotension, Dysautonomic | Phase 1 / Phase 2 | Recruiting | Julien Bally | 36 | 2025-07-18 | 2026-01-29 |
| Sustained Release Oral Formulation for Treatment of Parkinson's Disease levodopa/carbidopa oral formulation A, levodopa/carbidopa oral formulation B - Healthy Volunteers | Early Phase 1 | Completed | University of Minnesota | 6 | 2025-06-12 | 2026-06-25 |
| A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations HRG2010; Sustained-release Carbidopa/Levodopa administered placebo, Sustained-release Carbidopa/Levodopa; HRG2010 placebo - Parkinson's Disease | Phase 3 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 165 | 2024-11-06 | 2026-06-08 |
| Dopamine, Reward Learning and Sex Hormones Levodopa administration, Placebo administration - Hormonal Changes, Menstrual Cycle | Not applicable | Unknown | University Hospital Tuebingen | 90 | 2024-05-01 | 2024-05-09 |
| Bioequivalence Study of Entacapone,Levodopa and Carbidopa Tablets in the Postprandial State in Healthy Chinese Subjects Test (T) Entacapone,Levodopa and Carbidopa Tablets (II), Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II) - Healthy | Phase 1 | Unknown | The Affiliated Hospital of Qingdao University | 36 | 2023-12-20 | 2023-12-22 |
| Dopaminergic Therapy for Anhedonia - 2 Carbidopa Levodopa, Placebo - Anhedonia, Depression | Phase 4 | Recruiting | Emory University | 70 | 2023-11-21 | 2026-01-28 |
| Basic and Clinical Studies of Levodopa/Carbidopa/Entacapone in the Treatment of Early Parkinson's Disease levodopa/carbidopa/entacapone - Parkinson Disease | Phase 4 | Unknown | Second Affiliated Hospital of Soochow University | 60 | 2023-11-15 | 2024-02-01 |
| Comparison of Dopamin Level in Idiopathic Parkinson's Patients Levodopa - Parkinson Disease, Treatment Adherence | Phase 4 | Unknown | Ankara Ataturk Sanatorium Training and Research Hospital | 96 | 2023-10-01 | 2023-11-28 |
| Bioequivalence Study of Entacapone,Levodopa and Carbidopa Tablets in Healthy Chinese Subjects Test (T) Entacapone,Levodopa and Carbidopa Tablets (II), Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II) - Healthy | Phase 1 | Unknown | The Affiliated Hospital of Qingdao University | 68 | 2023-08-17 | 2023-08-04 |
| Pharmacokinetics,Pharmacodynamics,Efficacy and Safety of HRG2010 in Parkinson's Disease Patients With Motor Fluctuations HRG2010(I), HRG2010(II), Sustained-release Carbidopa/Levodopa - Parkinson's Disease | Phase 2 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 61 | 2023-05-16 | 2024-09-26 |
| Treating Early Stage Diabetic Retinopathy Sinemet CR, placebo - Diabetic Retinopathy | Early Phase 1 | Enrolling by invitation | VA Office of Research and Development | 244 | 2022-07-01 | 2026-04-07 |
| Opicapone as Adjunctive Therapy to Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease Opicapone 50 mg, Duodopa - Parkinson Disease, Effect of Drug | Not applicable | Completed | University Hospital of Ferrara | 22 | 2022-07-01 | 2025-03-03 |
| Levodopa for Diabetic Retinopathy Levodopa, Placebo - Diabetic Retinopathy | Phase 2 | Completed | Emory University | 230 | 2022-04-18 | 2026-03-03 |
| Bioavailability of Levodopa 250 mg and Carbidopa 25 mg With Regards to Reference Product Levodopa 250mg and Carbidopa 25mg Test Drug tablet, Levodopa 250mg and Carbidopa 25mg Referent Product tablet - Bioequivalence | Phase 1 | Completed | Laboratorios Andromaco S.A. | 44 | 2022-02-14 | 2022-03-08 |
| Clinical Study of Stalevo in the Treatment of Early Parkinson's Disease Stalevo, Carbidopa and Levodopa Controlled Release Tablets - Parkinson Disease | Phase 4 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 180 | 2022-01-01 | 2023-02-16 |
Showing 20 of 137. Sign in to see all of them.
Parkinson Disease (89) · Dyskinesias (11) · Depression (6) · Cocaine-Related Disorders (5) · Cognitive Dysfunction (4) · Movement Disorders (4) · Angelman Syndrome (3) · Depressive Disorder, Major (3) · Restless Legs Syndrome (3) · Anhedonia (2) · Brain Diseases (2) · Central Nervous System Diseases (2) · Diabetic Retinopathy (2) · Disruptive, Impulse Control, and Conduct Disorders (2) · Dysthymic Disorder (2)
Bial - Portela C S.A. (10) · Orion Corporation, Orion Pharma (8) · National Institute of Neurological Disorders and Stroke (NINDS) (7) · NeuroDerm Ltd. (5) · University Hospital Muenster (5) · Emory University (4) · New York State Psychiatric Institute (4) · Novartis (4) · Intec Pharma Ltd. (3) · Merck Sharp & Dohme LLC (3) · The University of Texas Health Science Center, Houston (3) · University Hospital, Toulouse (3) · Jiangsu HengRui Medicine Co., Ltd. (2) · Oregon Health and Science University (2) · Rush University Medical Center (2)
United States (52) · Germany (17) · Canada (10) · China (10) · Israel (9) · Finland (8) · Italy (8) · United Kingdom (8) · France (7) · Portugal (6) · Ukraine (6) · Spain (5) · Austria (4) · Switzerland (4) · Bulgaria (3)
Caterina Breitenstein, PhD (4) · Stefan Knecht, MD (4) · Bret Rutherford, MD (2) · Jennifer Felger, PhD (2) · Joaquim Ferreira, MD, PhD (2) · Kathryn Anne Chung, MD (2) · Kevin J Black, MD (2) · Mika Scheinin, MD (2) · Wen-Hann Tan, BMBS (2) · Yu Cao (2) · Adam Bisaga, M.D. (1) · Aila Holopainen, MSc (1)
PMID 10816186, PMID 11035889, PMID 11391738, PMID 12112073, PMID 12465061, PMID 12498954, PMID 12505794, PMID 16874752, PMID 16880771, PMID 16929307, PMID 17138744, PMID 17417738, PMID 19058133, PMID 19127579, PMID 19146929, PMID 19190638, PMID 19846332, PMID 19877202, PMID 20057930, PMID 20582993, PMID 21060282, PMID 21315654, PMID 21553090, PMID 22101745, PMID 22316635, PMID 22549097, PMID 23589371, PMID 25008546, PMID 25588456, PMID 25758422, PMID 26336641, PMID 26347184, PMID 26725544, PMID 27942720, PMID 28027332, PMID 28679598, PMID 28827011, PMID 29352722, PMID 29910127, PMID 30361296, PMID 31127735, PMID 31178096, PMID 31378952, PMID 32597817, PMID 32919398, PMID 33164945, PMID 34260994, PMID 35148289, PMID 36402160, PMID 38850081
P50DA009262 (2), 2008 (1), 2009 (1), 2018 (1), 2019 (1), 2025 (1), K23DK144718 (1), P50DA009236 (1), P50NS123103 (1), R01DA023608 (1), R01DA034131 (1), R01MH073856 (1), R01MH123660 (1), R21NS114749 (1), R33MH108753 (1)